Britta Weber1, Henrik Hager2, Boe S Sorensen3, Tine McCulloch4, Anders Mellemgaard5, Azza Ahmed Khalil6, Ebba Nexo3, Peter Meldgaard7. 1. Department of Clinical Biochemistry, Aarhus University Hospital, Aarhus, Denmark; Department of Oncology, Aarhus University Hospital, Aarhus, Denmark. 2. Department of Pathology, Aarhus University Hospital, Aarhus, Denmark. 3. Department of Clinical Biochemistry, Aarhus University Hospital, Aarhus, Denmark. 4. Department of Oncology, Aalborg University Hospital, Denmark. 5. Department of Oncology, Herlev Hospital, Herlev, Denmark. 6. Department of Oncology, Aarhus University Hospital, Aarhus, Denmark. 7. Department of Oncology, Aarhus University Hospital, Aarhus, Denmark. Electronic address: petemeld@rm.dk.
Abstract
OBJECTIVES: In 2008, we initiated a prospective study to explore the frequency and predictive value of epidermal growth factor receptor (EGFR) mutations in an unselected population of Danish patients with non-small cell lung cancer offered treatment with erlotinib, mainly in second-line. MATERIALS AND METHODS: Four hundred and eighty eight patients with advanced NSCLC were included. The mutation status was assessed using the cobas EGFR Mutation Test. Erlotinib was administrated (150 mg/d) until disease progression or unacceptable toxicities occurred. The primary endpoint was progression-free survival. Secondary endpoints were overall survival and response. RESULTS: Biopsies were retrieved from 467 patients, and mutation results obtained for 462. We identified 57 (12%) patients with EGFR mutations: 33 exon 19 deletions, 13 exon 21 mutations, 5 exon 18 mutations, 3 exon 20 insertions, 1 exon 20 point mutation (S768I), and two complex mutations. Seven percent of the patients were never smokers. The differences in median progression-free survival and overall survival between the mutated group and the wild-type group were 8.0 vs. 2.5 months, p<0.001 and 12.1 vs. 3.9 months, p<0.001. Performance status (0-1 vs. 2-3) and line of treatment (1st vs. 2nd and 3rd) had no influence on outcome in EGFR-mutated patients. CONCLUSION: We found a higher frequency of EGFR mutations than expected in a cohort with less than 10% never smokers. The outcome after treatment with erlotinib was much better in patients with EGFR mutations than in patients with wild-type EGFR and was independent of performance status and treatment line in EGFR-mutated patients.
OBJECTIVES: In 2008, we initiated a prospective study to explore the frequency and predictive value of epidermal growth factor receptor (EGFR) mutations in an unselected population of Danish patients with non-small cell lung cancer offered treatment with erlotinib, mainly in second-line. MATERIALS AND METHODS: Four hundred and eighty eight patients with advanced NSCLC were included. The mutation status was assessed using the cobas EGFR Mutation Test. Erlotinib was administrated (150 mg/d) until disease progression or unacceptable toxicities occurred. The primary endpoint was progression-free survival. Secondary endpoints were overall survival and response. RESULTS: Biopsies were retrieved from 467 patients, and mutation results obtained for 462. We identified 57 (12%) patients with EGFR mutations: 33 exon 19 deletions, 13 exon 21 mutations, 5 exon 18 mutations, 3 exon 20 insertions, 1 exon 20 point mutation (S768I), and two complex mutations. Seven percent of the patients were never smokers. The differences in median progression-free survival and overall survival between the mutated group and the wild-type group were 8.0 vs. 2.5 months, p<0.001 and 12.1 vs. 3.9 months, p<0.001. Performance status (0-1 vs. 2-3) and line of treatment (1st vs. 2nd and 3rd) had no influence on outcome in EGFR-mutated patients. CONCLUSION: We found a higher frequency of EGFR mutations than expected in a cohort with less than 10% never smokers. The outcome after treatment with erlotinib was much better in patients with EGFR mutations than in patients with wild-type EGFR and was independent of performance status and treatment line in EGFR-mutated patients.
Authors: Kristine R Jakobsen; Birgitte S Paulsen; Rikke Bæk; Kim Varming; Boe S Sorensen; Malene M Jørgensen Journal: J Extracell Vesicles Date: 2015-03-02
Authors: Kajsa Ericson Lindquist; Anna Karlsson; Per Levéen; Hans Brunnström; Christel Reuterswärd; Karolina Holm; Mats Jönsson; Karin Annersten; Frida Rosengren; Karin Jirström; Jaroslaw Kosieradzki; Lars Ek; Åke Borg; Maria Planck; Göran Jönsson; Johan Staaf Journal: Oncotarget Date: 2017-05-23
Authors: K R Jakobsen; C Demuth; A T Madsen; D Hussmann; J Vad-Nielsen; A L Nielsen; B S Sorensen Journal: Oncogenesis Date: 2017-04-03 Impact factor: 7.485
Authors: Dong Soo Lee; Yeon Sil Kim; Chul Seung Kay; Sung Hwan Kim; Chang Dong Yeo; Jin Woo Kim; Seung Joon Kim; Young Kyoon Kim; Yoon Ho Ko; Jin Hyoung Kang; Kyo Young Lee Journal: Medicine (Baltimore) Date: 2016-02 Impact factor: 1.817